KR890006244A - Ll- e33288 항종양제의 이황 유사물과 그 제조 방법 및 이용 - Google Patents

Ll- e33288 항종양제의 이황 유사물과 그 제조 방법 및 이용 Download PDF

Info

Publication number
KR890006244A
KR890006244A KR1019880014245A KR880014245A KR890006244A KR 890006244 A KR890006244 A KR 890006244A KR 1019880014245 A KR1019880014245 A KR 1019880014245A KR 880014245 A KR880014245 A KR 880014245A KR 890006244 A KR890006244 A KR 890006244A
Authority
KR
South Korea
Prior art keywords
divalent
radicals
hydrogen
heterocycloalkyl
alkyl radical
Prior art date
Application number
KR1019880014245A
Other languages
English (en)
Other versions
KR970011385B1 (ko
Inventor
제임즈 맥가런 윌리엄
리온 새시버 마틴
에이 엘레스태드 조오지
Original Assignee
알퐁스 아아르 노에
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알퐁스 아아르 노에, 아메리칸 사이아나밋드 캄파니 filed Critical 알퐁스 아아르 노에
Publication of KR890006244A publication Critical patent/KR890006244A/ko
Application granted granted Critical
Publication of KR970011385B1 publication Critical patent/KR970011385B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

LL- E33288 항종양제의 이황 유사물과 그 제조 방법 및 이용
제1도는 LL-E33288r2-Ⅰ의 자외선 스펙트럼이다.
제2도는 LL-E33288r2-Ⅰ의 핵자기 공명 스펙트럼이다.
제Ⅲ도는 LL-E33288r2-Ⅰ의 적외선 스펙트럼이다.
제Ⅳ도는 LL-E33288r2-Ⅰ의 질량 스펙트럼이다.
제Ⅴ도는 LL-E33288r2-Ⅰ의 핵자기 공명 스펙트럼이다.
제Ⅵ도는 LL-E33288r2-Ⅰ의 질량 스펙트럼이다.
본 내용은 요부 건이므로 전문 내용을 수록하지 않음

Claims (10)

  1. 하기 a)-d)를 갖는 항종양제 LL-E33288r2-Ⅰ:a)제1도에 보여진 바와같은 자외선 스펙트럼; b)제2도에 보여진 바와같은 핵자기공명 스펙트럼; c)제Ⅲ도에 보여진 바와 같은 적외선 스펙트럼; 및 d) 제Ⅳ도에 보여진 바와같은 질량 스펙트럼.
  2. 항종양제 LL-E33288r2-Ⅰ-Br
  3. 하기 일반식의 항생물질 CL-1724-1577E,CL-1577D,CL-1577B,CL-1577A,PD 115028,PD114759, FR-900406, FR-900405, BBm-1675, LL-E33288 a₁-Br, a₁-Ⅰ,a₂-Br a₂-Ⅰ,a₃-Br, a₃-Ⅰ,a₃-Br ,a₃- I, a₄-Br, β₁-Br, β₁- I,β<SB<2>/SB>I ,￦1Br, r₁Ⅰ,∂1-I 의 치환 이황화물 유사물;
    X는 요오드 또는 브롬이고; Sp는 직체 또는 측쇄이가(C₁-C₁8)라디칼; 이가 아릴 또는 헤테로아릴 라디칼, 이가(C₁-C₁8)시클로아킬 또는 헤테로시클로알킬 라디칼, 이가 (C₁-C₁8)아릴알킬 헤테로 아릴알킬 라디칼, 이가 (C₁-C₁8)시클로알킬알킬 또는 헤테로시클로 알킬알킬 라디칼, 또는 이가 (C₁-C₁8)불포화아킬 라디칼이며; Q는 수소, 할로겐, 아미노, 알킬아미노, 디알킬아미노, 피페리디노, 피롤리디노, 피페라지노, 카르복실, 카르복스알데히드; 저급 알콕시, 히드록시, 티올, 저급 알킬디카르복실, -CONHNH₂-NHCONHNH₂,-CSNHNH₂-NHCSNHNH₂또는 -ONH₂이다; (단, Sp가 에틸리덴일때, Q가 수소이면 안된다.)
  4. LL-E33288r₁-Ⅰ의 이황화에틸 유사물.
  5. 제Ⅵ도에 보여진 바와같은 질량 스펙트럼과 제Ⅴ도에 보여진 바와같은 핵자기 공명 스펙트럼을 갖는 LL-E33288r₁-Ⅰ의 Ⅰ-메틸-1 프로필 이황화물 유사물.
  6. LL-E33288r₁-Ⅰ의 Ⅰ-메틸-Ⅰ-프로필 이황화물 유사물.
  7. 제3항에 있어서, 헤테로 아릴알킬 라디칼이 7-아미노--4-메틸-쿠마린인 화합물.
  8. 하기의 삼황화알킬 항생물질을 1-48시간동안 -10℃내지 -30℃, 아세토니트릴내에서 적적히 치환된 메르캅탄과 반응시키는 것을 포함하는, 하기 일반식의 항생물질 CL-1724-1577E,CL-1577D,CL-1577B,CL-1577A,PD 115028,PD114759, FR-900406, FR-900405, BBm-1675, LL-E33288 Br ,a₃- I, a₄-Br, β₁-Br, β₁- I,β<SB<2>/SB>I ,￦1Br, r₁Ⅰ,∂1-I 의 치환 이황화물 유사물을 제조하는 방법.
    X는 요오드 또는 브롬이고; Sp는 직쇄 또는 측쇄이가(C₁-C18)라디칼; 이가 아릴 또는 헤테로아릴 라디칼, 이가(C₁-C18)시클로알킬 또는 헤테로시클로알킬 라디칼, 이가(C₁-C18)아릴알킬 헤테로 아릴알킬 라디칼, 이가 (C₁-C18)시클로알킬알킬 똔든 헤테로시클로 알킬알킬 라디칼, 또는 이가 (C₁-C18)불포화 알킬 라디칼이며; Q는 수소, 할로겐, 아미노, 알킬아미노, 디알킬아미노, 피페리디노, 피롤리디노, 리페라지노, 카르복실, 카르복스알데히디; 저급 알콕시, 히드록시, 티올, 저급 알킬디카르복실 - CONHNH₂-NHCONHNH₂-CSNHNH₂또는 -ONH₂이다; (단, Sp가 에틸리덴일때, Q가 수소이면 안된다.)
  9. 하기 일반식의 CL-1724-1577E,CL-1577D,CL-1577B,CL-1577A,PD 115028,PD114759, FR-900406, FR-900405, BBm-1675, LL-E33288 Br ,a₃- I, a₄-Br, β₁-Br, β₁- I,β<SB<2>/SB>I ,￦1Br, r₁Ⅰ,∂1-I 의 치환 이황화물 유사물로부터 선택된 화합물 향균적으로 효과적인 양을 온혈 동물에게 투여하는 것을 포함하는 온혈동물의 세균 감염의 치료방법;
    X는 요오드 또는 브롬이고; Sp는 직쇄 또는 측쇄이가(C₁-C18)라디칼; 이가 아릴 또는 헤테로아릴 라디칼, 이가(C₁-C18)시클로알킬 또는 헤테로시클로알킬 라디칼, 이가(C₁-C18)아릴알킬 헤테로 아릴알킬 라디칼, 이가 (C₁-C18)시클로알킬알킬 똔든 헤테로시클로 알킬알킬 라디칼, 또는 이가 (C₁-C18)불포화 알킬 라디칼이며; Q는 수소, 할로겐, 아미노, 알킬아미노, 디알킬아미노, 피페리디노, 피롤리디노, 리페라지노, 카르복실, 카르복스알데히디; 저급 알콕시, 히드록시, 티올, 저급 알킬디카르복실 - CONHNH₂-NHCONHNH₂-CSNHNH₂또는 -ONH₂이다; (단, Sp가 에틸리덴일때, Q가 수소이면 안된다.)
  10. 하기 일반식의 CL-1724-1577E,CL-1577D,CL-1577B,CL-1577A,PD 115028,PD114759, FR-900406, FR-900405, BBm-1675, LL-E33288 Br ,a₃- I, a₄-Br, β₁-Br, β₁- I,β<SB<2>/SB>I ,￦1Br, r₁Ⅰ,∂1-I 의 치환 이호아화물 유사물로부터 선택된 화합물의 종양학적(oncolytic)양을 포유 동물에게 투여하는 것을 포함하는, 포유동물의 종양의 성장 저지 방법.
    X는 요오드 또는 브롬이고; Sp는 직쇄 또는 측쇄이가(C₁-C18)라디칼; 이가 아릴 또는 헤테로아릴 라디칼, 이가(C₁-C18)시클로알킬 또는 헤테로시클로알킬 라디칼, 이가(C₁-C18)아릴알킬 헤테로 아릴알킬 라디칼, 이가 (C₁-C18)시클로알킬알킬 똔든 헤테로시클로 알킬알킬 라디칼, 또는 이가 (C₁-C18)불포화 알킬 라디칼이며; Q는 수소, 할로겐, 아미노, 알킬아미노, 디알킬아미노, 피페리디노, 피롤리디노, 리페라지노, 카르복실, 카르복스알데히디; 저급 알콕시, 히드록시, 티올, 저급 알킬디카르복실 - CONHNH₂-NHCONHNH₂-CSNHNH₂또는 -ONH₂로부터 선택된 기이다.; (단, Sp가 에틸리덴일때, Q가 수소이면 안된다.)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880014245A 1987-10-30 1988-10-30 Ll-e33288 항종양제의 이황 유사물과 그 제조 방법 및 이용 KR970011385B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11494087A 1987-10-30 1987-10-30
US114,940 1987-10-30
US07/114,940 1987-10-30

Publications (2)

Publication Number Publication Date
KR890006244A true KR890006244A (ko) 1989-06-12
KR970011385B1 KR970011385B1 (ko) 1997-07-10

Family

ID=22358378

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019880014246A KR0133130B1 (ko) 1987-10-30 1988-10-30 메틸트리티오 항종양제의 표적형태인 약제-담체 결합제와 그 제조방법
KR1019880014245A KR970011385B1 (ko) 1987-10-30 1988-10-30 Ll-e33288 항종양제의 이황 유사물과 그 제조 방법 및 이용

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1019880014246A KR0133130B1 (ko) 1987-10-30 1988-10-30 메틸트리티오 항종양제의 표적형태인 약제-담체 결합제와 그 제조방법

Country Status (19)

Country Link
EP (2) EP0313874B1 (ko)
JP (2) JP2820256B2 (ko)
KR (2) KR0133130B1 (ko)
AR (1) AR246083A1 (ko)
AT (2) ATE112172T1 (ko)
AU (2) AU612714B2 (ko)
BR (1) BR1100939A (ko)
CA (1) CA1321582C (ko)
DE (2) DE3889063T2 (ko)
DK (2) DK602488A (ko)
ES (2) ES2061586T3 (ko)
FI (2) FI95204C (ko)
HK (2) HK131897A (ko)
IE (2) IE65053B1 (ko)
IL (2) IL87947A (ko)
NO (2) NO176480C (ko)
NZ (2) NZ226727A (ko)
PT (2) PT88882B (ko)
ZA (2) ZA888123B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL115770A (en) * 1989-04-14 1999-03-12 American Cyanamid Co Substituted disulfides of formula q-sp-ss-w their preparation and use for inhibiting the growth of tumours and for treating bacterial infections
GB9007384D0 (en) * 1990-04-02 1990-05-30 Duncan Ruth Coupling between polymers and other organic molecular entities utilising thiol-specific reactive groups
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
PT2261335T (pt) 1998-11-27 2017-09-08 Ucb Pharma Sa Composições e métodos para aumentar a mineralização óssea
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
MEP2808A (xx) 2003-06-16 2010-02-10 Celltech R & D Inc Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
US8841092B2 (en) * 2006-08-30 2014-09-23 Wisconsin Alumni Research Foundation Reversible natural product glycosyltransferase-catalyzed reactions, compounds and related methods
KR100979928B1 (ko) * 2008-07-16 2010-09-03 한주학 수직축형 부력풍차
SI3066074T1 (sl) * 2013-11-04 2020-03-31 Pfizer Inc. Intermediati in postopki za sintetizacijo derivatov kaliheamicina
EP3573995A1 (en) * 2017-01-24 2019-12-04 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
EP3924387A2 (en) * 2019-02-15 2021-12-22 University Of Southern California Lym-1 and lym-2 antibody compositions and improved car constructs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430943A1 (fr) * 1978-07-13 1980-02-08 Toyo Jozo Kk Nouveaux derives disulfures
DE3175151D1 (en) * 1980-05-21 1986-09-25 Teijin Ltd Reactive polymer and process for the preparation thereof
US4530835A (en) * 1983-07-08 1985-07-23 Warner-Lambert Company CL-1577 Antibiotic compounds and their production
CA1314245C (en) * 1984-05-23 1993-03-09 Franz Jansen Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators
DE3588213T2 (de) * 1984-11-16 1999-09-30 American Cyanamid Co Antitumorale Antibiotika (Komplex LL-E-33288)
EP0330874A3 (en) * 1988-02-29 1989-10-18 American Cyanamid Company Antibacterial and antitumor agents LL-E33288 epsilon-I and LL-E33288-epsilonBr, with processes and intermediates for producing said agents
EP0342341A3 (en) * 1988-05-17 1991-07-24 American Cyanamid Company Process for producing antitumor antibiotic ll-e33288gamma2

Also Published As

Publication number Publication date
HK131897A (en) 1997-10-03
NO176480C (no) 1995-04-12
EP0313874A3 (en) 1990-05-09
IE883261L (en) 1989-04-30
AU2449488A (en) 1989-05-04
NO176480B (no) 1995-01-02
FI884983A0 (fi) 1988-10-28
JP2720933B2 (ja) 1998-03-04
NO884834D0 (no) 1988-10-28
NO884833D0 (no) 1988-10-28
FI91262B (fi) 1994-02-28
KR970011385B1 (ko) 1997-07-10
DK602488D0 (da) 1988-10-28
ATE104309T1 (de) 1994-04-15
JP2820256B2 (ja) 1998-11-05
NO884834L (no) 1989-05-02
NO173506C (no) 1993-12-22
ZA888127B (en) 1989-07-26
DE3889063T2 (de) 1994-12-01
ATE112172T1 (de) 1994-10-15
IL87946A0 (en) 1989-03-31
DE3851682T2 (de) 1995-05-04
AR246083A1 (es) 1994-03-30
PT88882B (pt) 1993-01-29
KR890006245A (ko) 1989-06-12
DK602588A (da) 1989-05-01
IL87947A (en) 1995-05-26
FI884984A0 (fi) 1988-10-28
IE883262L (en) 1989-04-30
DK602588D0 (da) 1988-10-28
IL87947A0 (en) 1989-03-31
CA1321582C (en) 1993-08-24
IL87946A (en) 1995-06-29
AU612714B2 (en) 1991-07-18
FI95204B (fi) 1995-09-29
HK131997A (en) 1997-10-03
JPH01193282A (ja) 1989-08-03
DE3889063D1 (de) 1994-05-19
EP0313873B1 (en) 1994-09-28
DK174739B1 (da) 2003-10-13
AU618763B2 (en) 1992-01-09
AU2448988A (en) 1989-05-04
NO173506B (no) 1993-09-13
EP0313874A2 (en) 1989-05-03
NZ226726A (en) 1991-08-27
PT88881B (pt) 1993-01-29
NZ226727A (en) 1991-12-23
IE65989B1 (en) 1995-11-29
FI884984A (fi) 1989-05-01
ZA888123B (en) 1989-07-26
EP0313874B1 (en) 1994-04-13
ES2061586T3 (es) 1994-12-16
FI884983A (fi) 1989-05-01
DE3851682D1 (de) 1994-11-03
ES2059464T3 (es) 1994-11-16
DK602488A (da) 1989-05-01
FI95204C (fi) 1996-01-10
EP0313873A1 (en) 1989-05-03
KR0133130B1 (ko) 1998-04-17
FI91262C (fi) 1994-06-10
BR1100939A (pt) 1999-08-31
IE65053B1 (en) 1995-10-04
JPH0296599A (ja) 1990-04-09
NO884833L (no) 1989-05-02

Similar Documents

Publication Publication Date Title
KR890006244A (ko) Ll- e33288 항종양제의 이황 유사물과 그 제조 방법 및 이용
ES8802522A1 (es) Un procedimiento para preparar nuevos derivados macrociclicos de lactona
ES445075A1 (es) Un procedimiento para la preparacion de nuevos acidos fenoxi-alquil-carboxilicos.
KR910000631A (ko) 디-3급-부틸(히드록시)페닐 티오 치환된 히드록삼산 유도체
SE8804586L (sv) 1,4-dihydro-4-oxonaftyridinderivat och salter daerav foerfarande foer framstaellning av dessa jaemte antibakteriella medel innefattande dessa
JPS55111499A (en) Glucosamine derivative and its preparation
AU3597093A (en) Gene transfer in poultry by introduction of embryo cells (in ovo)
IE820353L (en) A control or calibration serum
HU9300192D0 (en) Polypeptide compounds promoting growth hormone emission
AU564169B2 (en) Sulphur-containing indole derivatives
KR890009962A (ko) 매뉴마이신 유도체, 이의 제조방법 및 용도
SE8601852D0 (sv) Cyklopentyletrar och deras framstellning och farmaceutiska beredning
DK0475781T3 (da) Akvatiske antitilsmudsningspræparater
FI871409A (fi) N,n&#39;-substituerade bis-(2,4-diamino-s-triazin-6-yl)-tetrasulfider och deras disproportioneringsproduter, foerfarande foer deras framstaellning och deras anvaendning i vulkaniserbara kautschukblandningar.
EP0332156A3 (en) Cephem compounds and processes for preparation thereof
ATE84720T1 (de) Verwendung von adenosinderivaten zur herstellung von arzneimitteln mit immunstimulierender wirkung.
GB2006759A (en) omega -Mercapto-propionamides and Pharmaceutical Preparations containing them
KR880013963A (ko) 글루코피라노즈 유도체
DE69107080D1 (de) Organozinnverbindungen mit Antitumoraktivität und Zusammensetzungen mit Antitumorwirkung.
FI834594A (fi) Antibiotikum a51568 faktorerna a och b.
GB1178982A (en) Anthelmintic Compositions
BG95629A (en) Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
DE3660426D1 (de) Urea acryl derivatives
EP0338824A3 (en) Esters of 6-beta-(alpha-oxyimino)-acylamino-penicillanic acid derivatives
Safrit et al. Length-weight relationships for gulf flounder, Paralichthys albigutta, from North Carolina.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20091012

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee